Targeting TGFβ-mediated processes in cancer

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 2, 2009, Pages 253-263

  Romano, M F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antisense molecule; Kinase inhibitor; Metastasis; Oncosuppression; Signal transduction; Smad; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; AP 11014; AP 12009; FK 506 BINDING PROTEIN; GC 1008; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INTERLEUKIN 8; JANUS KINASE; LERDELIMUMAB; LY 2109761; LY 550410; LY 580276; METELIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SB 505124; SD 093; SD 208; SM 16; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; LIGAND;

AUTOCRINE EFFECT; CARCINOGENESIS; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARACRINE SIGNALING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CANCER INVASION; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG DESIGN; HUMANS; LIGANDS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFORMING GROWTH FACTOR BETA;

EID: 62149151395     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Massagué J: How cells read TGFβ signals. Nat Rev Mol Cell Biol (2000) 1(3):169-178. • Reviews the networks cell-specific molecules that orchestrate the TGFβ response.
2. Massagué J, Blain SW, Lo RS: TGFβ signaling in growth control, cancer and heritable disorders. Cell (2000) 103(2):295-309.
3. Siegel PM, Massagué J: Cytostatic and apoptotic actions of TGFβ in homeostasis and cancer. Nat Rev Cancer (2005) 3(11):807-821.
4. Bierie B, Moses HL: Tumour microenvironment: TGFβ: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 6(7):506-520.
5. Go C, Li P, Wang XJ: Blocking transforming growth factor-β signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis. Cancer Res (1999) 59(12):2861-2868.
6. Go C, He W, Zhong L, Li P, Huang J, Brinkley BR, Wang XJ: Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFRII. Oncogene (2000) 19(32):3623-3631.
7. Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA, Moses HL: Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol (2003) 163(4):1539-1549.
8. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ: TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell (1996) 86(4):531-542.
9. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM: TGFβ switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest (2003) 112(7):1116-1124. •• Demonstration of the dual role of TGFβ in a breast cancer model.
10. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, Muller WJ, Moses HL: Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res (2005) 65(6):2296-2302.
11. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J: Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA (2003) 100(14):8430-8435.
12. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL: Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor-β 1. Mol Cell Biol (2003) 23(23):8691-8703.
13. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL: Conditional overexpression of active transforming growth factor 1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res (2004) 64(24):9002-9011.
14. Muraoka-Cook RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V et al: Blockade of TGFβ inhibits mammary tumor cell viability, migration and metastases. J Clin Invest (2002) 109(12):1551-1559.
15. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL: Activated type I TGF receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene (2006) 25(24):3408-3423. • First demonstration of the existence of cross-talk between TGFβ and the pro-tumorigenic PI3k signaling pathway.
16. Yingling JM, Blanchard KL, Sawyer JS: Development of TGFβ signalling inhibitors for cancer therapy. Nat Rev Drug Discov (2004) 3(12):1011-1022. •• An outstanding review of the medicinal chemistry of TGFβ signaling inhibitors in cancer therapy.
17. Elliot RL, Blobe GC: Role of transforming growth factor-β in human cancer. J Clin Oncol (2005) 23(9):2078-2093.
18. Dumont N, Arteaga CL: Targeting the TGFβ signaling network in human neoplasia. Cancer Cell (2003) 3(6):531-536.
19. Arteaga CL: Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev (2006) 16(1):30-37.
20. Massagué J: TGFβ in cancer. Cell (2008) 134(2):215-230. •• An up-to-date review on the knowledge of the mechanistic basis, clinical relevance and therapeutic potential of TGFβ pathway in cancer.
21. Cheifetz S, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R, Massagué J: The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors. Cell (1987) 48(3):409-415.
22. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK: The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell (1996) 86(3):435-444.
23. Janknecht R, Wells NJ, Hunter T: TGFβ-stimulated cooperation of Smad proteins with the coactivators CBP/p300. Genes Dev (1998) 12(14):2114-2119.
24. Lu T, Tian L, Han Y, Vogelbaum M, Stark GR: Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways. Proc Natl Acad Sci USA (2007) 104(11):4365-4370.
25. Suzuki K, Wilkes MC, Garamszegi N, Edens M, Leof EB: Transforming growth factor β signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses. Cancer Res (2007) 67(8):3673-3682.
26. Levy L, Hill CS: Alterations in components of the TGFβ superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev (2006) 17(1-2):41-58.
27. Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T: TGFBR1*6A and cancer: A meta-analysis of 12 case-control studies. J Clin Oncol (2004) 22(4):756-758.
28. Dong M, Blobe GC: Role of transforming growth factor-β in hematologic malignancies. Blood (2006) 107(12):4589-4596.
29. Jaffee EM, Hruban RH, Canto M, Kern SE: Focus on pancreas cancer. Cancer Cell (2002) 2(1):25-28.
30. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S et al: The consensus coding sequences of human breast and colorectal cancers. Science (2006) 314(5797):268-274.
31. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J: High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell (2007) 11(2):147-160.
32. Gomis RR, Alarcón C, Nadal C, Van Poznak C, Massagué J: C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell (2006) 10(3):203-214.
33. Yi JY, Shin I, Arteaga CL: Type I transforming growth factor β receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem (2005) 280(11):10870-10876.
34. Petritsch C, Beug H, Balmain A, Oft M: TGFβ inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev (2000) 14(24):3093-3101.
35. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL: Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 12(1):27-36.
36. Seoane J, Le HV, Shen L, Anderson SA, Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell (2004) 117(2):211-223.
37. Conery AR, Cao Y, Thompson EA, Townsend CM Jr, Ko TC, Luo K: Akt interacts directly with Smad3 to regulate the sensitivity to TGFβ induced apoptosis. Nat Cell Biol (2004) 6(4):366-372.
38. Remy I, Montmarquette A, Michnick SW: PKB/Akt modulates TGFβ signalling through a direct interaction with Smad3. Nat Cell Biol (2004) 6(4):358-365.
39. Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin M, Wang XJ: Distinct mechanisms of TGFβ1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest (2005) 115(7):1714-1723.
40. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor-β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res (2006) 66(4):2202-2209.
41. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol (2003) 15(6):740-746.
42. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S et al: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 6(1):17-32.
43. De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol (2003) 200(4):429-447.
44. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-β regulation of immune responses. Annu Rev Immunol (2006) 24:99-146.
45. Kurimoto M, Endo S, Arai K, Horie Y, Nogami K, Takaku A: TM-1 cells from an established human malignant glioma cell line produce PDGF, TGFα, and TGFβ which cooperatively play a stimulatory role for an autocrine growth promotion. J Neurooncol (1994) 22(1):33-44.
46. Rodeck U, Nishiyama T, Mauviel A: Independent regulation of growth and Smad-mediated transcription by transforming growth factor β in human melanoma cells. Cancer Res (1999) 59(3):547-550.
47. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J: TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 133(1):66-77. •• Provides clinical, functional, and molecular evidence that TGFβ primes cancer cells in the breast tumor microenvironment for metastasis to the lungs.
48. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J: Genes that mediate breast cancer metastasis to lung. Nature (2005) 436(7050):518-524.
49. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther (2007) 6(10):2609-2617.
50. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE: A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res (2007) 67(5):2351-2359. • The small-molecule TGFβ inhibitor SM-16 demonstrated potent activity against mesothelioma by an immune-mediated mechanism of CD8+ antitumor response.
51. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG: Transforming growth factor-1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways. Oncogene (2003) 22(28):4314-4332.
52. Issing WJ, Liebich C, Wustrow TP, Ullrich A: Coexpression of epidermal growth factor receptor and TGFα and survival in upper aerodigestive tract cancer. Anticancer Res (1996) 16(1):283-288.
53. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer (2007) 120(4):781-787.
54. Sakata M, Kurachi H, Ikegami H, Jikihara H, Morishige K-I, Miyake A, Terakawa N, Tanizawa O: Autocrine growth mechanism by transforming growth factor (TGF)-β1 and TGF-β1-receptor regulation by epidermal growth factor in a human endometrial cancer cell line IK-90. Int J Cancer (2006) 54(5):862-867.
55. Reiss M, Barcellos-Hoff MH: Transforming growth factor-β in breast cancer: A working hypothesis. Breast Cancer Res Treat (1997) 45(1):81-95.
56. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL: Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 13(1):23-35.
57. Dalal BI, Keown PA, Greenberg AH: Immunocytochemical localization of secreted transforming growth factor-β 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol (1993) 143(2):381-389.
58. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massagué J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA (2005) 102(39):13909-13914. •• Demonstration that Smad4 contributes to the formation of osteolytic bone metastases and is essential for the induction of genes implicated in bone metastasis.
59. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br Med J (1995) 311(7011):977-980.
60. Comerci JT Jr, Runowicz CD, Fields AL, Romney SL, Palan PR, Kadish AS, Goldberg GL: Induction of transforming growth factor β-1 in cervical intraepithelial neoplasia in vivo after treatment with β-carotene. Clin Cancer Res (1997) 3(2):157-160.
61. Stoika R, Yakymovych M, Souchelnytskyi S, Yakymovych I: Potential role of transforming growth factor β1 in drug resistance of tumor cells. Acta Biochim Pol (2003) 50(2):497-508.
62. Romano S, Mallardo M, Chiurazzi F, Bisogni R, D'Angelillo A, Liuzzi R, Compare G, Romano MF: The effect of FK506 on transforming growth factor β signaling and apoptosis in chronic lymphocytic leukemia B cells. Haematologica (2008) 93(7):1039-1048.
63. Park SH, Lee SR, Kim BC, Cho EA, Patel SP, Kang HB, Sausville EA, Nakanishi O, Trepel JB, Lee BI, Kim SJ: Transcriptional regulation of the transforming growth factor β type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem (2002) 277(7):5168-5174.
64. Miyajima A, Asano T, Hayakawa M: Captopril restores transforming growth factor-β type II receptor and sensitivity to transforming growth factor-β in murine renal cell cancer cells. J Urol (2001) 165(2):616-620.
65. Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM: Inhibition of farnesyltransferase increases TGFβ type II receptor expression and enhances the responsiveness of human cancer cells to TGFβ. Oncogene (2000) 19(48):5525-5533.
66. Venkatasubbarao K, Ammanamanchi S, Brattain MG, Mimari D, Freeman JW: Reversion of transcriptional repression of Sp1 by 5 aza-2 deoxycytidine restores TGFβ type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. Cancer Res (2001) 61(16):6239-6247.
67. Gorelik L, Flavell RA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med (2001) 7(10):1118-1122.
68. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A et al: SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 64(21):7954-7961.
69. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M: RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 64(20):7596-7603.
70. Penafuerte C, Galipeau J: TGFβ secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother (2008) 57(8):1197-1206.
71. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E et al: Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol (2006) 24(29):4721-4730.
72. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM: Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 14(12):3966-3974.
73. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL: Inhibition of TGFβ with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest (2007) 117(5):1305-1313. •• Administration of ionizing radiation or doxorubicin in a mouse model of metastatic breast cancer caused increased circulating levels of TGFβ1 as well as increased circulating tumor cells and lung metastases. These effects were abrogated by administration of a neutralizing pan-TGFβ antibody.
74. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L: Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor β 2 affinity purification. J Immunol (1989) 142(5):1536-1541.
75. Cordeiro MF, Gay JA, Khaw PT: Human anti-transforming growth factor-β2 antibody: A new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci (1999) 40(10):2225-2234.
76. Thompson JE, Vaughan TJ, Williams AJ, Wilton J, Johnson KS, Bacon L, Green JA, Field R, Ruddock S, Martins M, Pope AR: A fully human antibody neutralising biologically active human TGFβ2 for use in therapy. J Immunol Methods (1999) 227(1-2):17-29.
77. Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA: The autocrine production of transforming growth factor-β 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol (1990) 145(5):1415-1422.
78. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, Lonning S et al: Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res (2006) 66(12):6327-6335.
79. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S et al: An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res (2008) 68(10):3835-3843.
80. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT: Evaluation of anti-TGFβ2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci (2003) 44(8):3394-3401.
81. Khaw P, Grehn F, Holló G, Overton B, Wilson R, Vogel R, Smith Z: A phase III study of subconjunctival human antitransforming growth factor β(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology (2007) 114(10):1822-1830.
82. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S et al: Add-on anti-TGFβ antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol (2003) 14(7):1816- 1824.
83. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J et al: Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 56(1):323-333.
84. NCT00356460: Safety and efficacy study of GC1008 to treat renal cell carcinoma or malignant melanoma. Genzyme Corp, Cambridge, MA, USA (2009).
85. Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A, Kalluri R: Integrin α1β1 and transforming growth factor-β1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol (2000) 157(5):1649-1659.
86. Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L: A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res (1999) 59(19):5041-5046.
87. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V et al: Blockade of TGFβ inhibits mammary tumor cell viability, migration and metastases. Clin Invest (2002) 109(12):1551-1559.
88. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR et al: Lifetime exposure to a soluble TGFβ antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 109(12):1607-1615.
89. Bandyopadhyay A, López-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ: Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res (2002) 62(16):4690- 4695.
90. Bandyopadhyay A, Wang L, López-Casillas F, Mendoza V, Yeh IT, Sun L: Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate (2005) 63(1):81-90.
91. Schlingensiepen KH, Bischof A, Egger T, Hafner M, Herrmuth H, Jachimczak P, Kielmanowicz M, Niewel M, Zavadova E, Stauder G: The TGFβ1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies. J Clin Oncol (2004) 22(14 Suppl): Abs 3132.
92. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J et al: Inhibition of TGFβ2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies. Oligonucleotides (2007) 17(2):201-212.
93. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S: Antisense therapeutics for tumor treatment: The TGFβ2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res (2008) 177:137-150.
94. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA (1996) 93(7):2909-2914.
95. Liau LM, Fakhrai H, Black KL: Prolonged survival of rats with intracranial C6 gliomas by treatment with TGFβ antisense gene. Neurol Res (1998) 20(8):742-747.
96. Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM: Transforming the TGFβ pathway: Convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr Opin Drug Discov Devel (2004) 7(4):437-445.
97. Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S et al: Synthesis and activity of new aryl- and heteroarylsubstituted 5,6-dihydro-4H-pyrrolo[1,2-b] pyrazole inhibitors of the transforming growth factor- type I receptor kinase domain. Bioorg Med Chem Lett (2004) 14(13):3581-3584.
98. Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS et al: Optimization of a dihydropyrrolopyrazole series of transforming growth factor-β type I receptor kinase domain inhibitors: Discovery of an orally bioavailable transforming growth factor-β receptor type I inhibitor as antitumor agent. J Med Chem (2008) 51(7):2302-2306.
99. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ: LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 7(4):829-840. • LY-2109761, in combination with gemcitabine, significantly decreased tumor burden, prolonged survival, and reduced spontaneous abdominal metastases in an orthotopic murine model of metastatic pancreatic cancer.
100. Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N et al: Kinetic characterization of novel pyrazole TGFβ receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry (2005) 44(7):2293-2304.
101. Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M: Targeting endogenous transforming growth factor β receptor signaling in Smad4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res (2004) 64(15):5200-5211.
102. DaCosta Byfield S, Major C, Laping NJ, Roberts AB: SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol (2004) 65(3):744-752.
103. Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P: Identification of Smad7, a TGFβ-inducible antagonist of TGFβ signalling. Nature (1997) 389(6651):631-635.
104. Iglesias M, Frontelo P, Gamallo C, Quintanilla M: Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas. Oncogene (2000) 19(36):4134-4145.
105. Cui Q, Lim SK, Zhao B, Hoffmann FM: Selective inhibition of TGFβ responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1, and CBP. Oncogene (2005) 24(24):3864-3874.
106. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Büchler MW, Falb D, Korc M: The TGFβ signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 18(39):5363-5372.
107. van Dijk MA, van de Winkel JG: Human antibodies as next generation therapeutics. Curr Opin Chem Biol (2001) 5(4):368-374.
108. Ling LE, Singh J, Chuaqui CE, Boriack-Sjodin PA, Lepage DJ, Silverio EL, Corbley MJ, Sun L, Papadatos JL, Shan F, Pontz T et al: The use of virtual screening in Alk5 kinase inhibitor discovery and validation of orally active Alk5 kinase inhibitors in oncology. In: Transforming Growth Factor-β in Cancer Therapy Vol II. Jakowlew SB (Ed), Humana Press, Totowa, NJ, USA (2008).
109. Fransvea E, Angelotti U, Antonaci S, Giannelli G: Blocking transforming growth factor-β up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. (Hepatology) (2008) 47(5):1557-1566.
110. Sinpitaksakul SN, Pimkhaokham A, Sanchavanakit N, Pavasant P: TGFβ1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway. Biochem Biophys Res Commun (2008) 371(4):713-718.
111. Noma K, Smalley KS, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ, Nakagawa H, Herlyn M: The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology (2008) 134(7):1981-1993.
112. TGFβ receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia (2005) 7(5):509-521.
113. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN: SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther (2004) 3(6):737-745.
114. Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M et al: SM16, an orally active tgfβ type I receptor inhibitor, prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol (2008) 28(4):665-671.
115. Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C et al: Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGFβ type I receptor inhibitors. J Med Chem (2004) 47(18):4494-4506.
116. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S et al: Synthesis and activity of new aryland heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem (2003) 46(19):3953-3956.
117. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL et al: Successful shape-based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg Med Chem Lett (2003) 13(24):4355-4359.
118. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G et al: Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res (2006) 12(14 Pt 1):4315-4330.
119. NATIONAL INSTITUTES OF HEALTH (Terabe M, Takaku S, Berzofsky JA): Synergistic effect of TGFβR; blockade and immunogenic agents on tumors. WO-2006089251 (2006).
120. BIOGEN INC (Lee WC, Carter MB, Sun L, Chuaqui C, Singh J, Boriack-Sjodin P, Choi MS): Preparation of (pyridinyl) (pyrimidinyl) imidazo[1,2-a]pyridines as TGFβ receptor type I antagonists for treatment of fibrotic disorders and tumors. WO-2004021989 (2004).
121. PFIZER PRODUCTS INC (Blumberg LC, Munchhof MJ) Preparation of 2-(triazolyl)pyridines and related compounds as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases. WO-2004026307 (2004).
122. SCIOS INC (Chakravarty S, Dugar S, Perumattam JJ, Schreiner GF, Liu DY, Lewicki JA) Preparation of quinazolines as p38-β kinase and TGFβ inhibitors. WO-2000012497 (2000).
123. (Munchhof MJ): Isothiazole derivatives. WO-2004067530 (2004).